Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.72 |
| ▸ | JAK1 | P23458 | 6/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636208 | 1.00 | TYK2 (0.72) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL21013819 | 0.91 | TYK2 (0.60) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL26629703 | 0.85 | TYK2 (0.78) | TYK2JAK1JAK2 | |
| SCHEMBL30636403 | 0.85 | TYK2 (0.78) | TYK2JAK1JAK2 | |
| SCHEMBL26462376 | 0.85 | TYK2 (0.73) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL25536722 | 0.84 | TYK2 (0.88) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL15713486 | 0.84 | TYK2 (0.71) | TYK2JAK1 | |
| SCHEMBL25536688 | 0.84 | TYK2 (0.88) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL30636240 | 0.84 | TYK2 (0.70) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL15713476 | 0.84 | TYK2 (1.00) | TYK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213308-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 苏州隆博泰药业有限公司 | 2023-11-09 | — | — | WO | claimed |
| WO-2023213308-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 苏州隆博泰药业有限公司 | 2023-11-09 | — | — | WO | disclosed |
| EP-3066078-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9987266-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987266-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170209426-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209426-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-9663467-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663467-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160280649-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280649-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015069310-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280649-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | TYK2, IFNAR1, IFNG | TYK2 1/4885JAK1 16/4885CYP2C19 1991/4885 |
| US-20170209426-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | IFNAR1, TYK2, IFNG | TYK2 2/4885JAK1 16/4885CYP2C19 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.